481 related articles for article (PubMed ID: 14751770)
21. Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease.
Dikranian K; Kim J; Stewart FR; Levy MA; Holtzman DM
Int J Clin Exp Pathol; 2012; 5(6):482-95. PubMed ID: 22949930
[TBL] [Abstract][Full Text] [Related]
22. Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice.
Héraud C; Goufak D; Ando K; Leroy K; Suain V; Yilmaz Z; De Decker R; Authelet M; Laporte V; Octave JN; Brion JP
Neurobiol Dis; 2014 Feb; 62():100-12. PubMed ID: 24076100
[TBL] [Abstract][Full Text] [Related]
23. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.
Gordon MN; Holcomb LA; Jantzen PT; DiCarlo G; Wilcock D; Boyett KW; Connor K; Melachrino J; O'Callaghan JP; Morgan D
Exp Neurol; 2002 Feb; 173(2):183-95. PubMed ID: 11822882
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation.
Koller EJ; Ibanez KR; Vo Q; McFarland KN; Gonzalez De La Cruz E; Zobel L; Williams T; Xu G; Ryu D; Patel P; Giasson BI; Prokop S; Chakrabarty P
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12779. PubMed ID: 34825397
[TBL] [Abstract][Full Text] [Related]
25. Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
Chen Y; Zhao S; Fan Z; Li Z; Zhu Y; Shen T; Li K; Yan Y; Tian J; Liu Z; Zhang B
Alzheimers Res Ther; 2021 Feb; 13(1):40. PubMed ID: 33563332
[TBL] [Abstract][Full Text] [Related]
26. [Generation of Tau/App/PS1 triple-transgenic mouse model and the study of its biological characteristics].
Wang LL; Na X; Zhu XN; Chen RZ; Wang H; Wang XL
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2012 Jul; 28(4):294-7. PubMed ID: 23156717
[TBL] [Abstract][Full Text] [Related]
27. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
29. Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 3×Tg-AD mice.
Yan XX; Cai Y; Shelton J; Deng SH; Luo XG; Oddo S; Laferla FM; Cai H; Rose GM; Patrylo PR
PLoS One; 2012; 7(11):e48782. PubMed ID: 23155407
[TBL] [Abstract][Full Text] [Related]
30. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
[TBL] [Abstract][Full Text] [Related]
31. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
33. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
Guo Q; Li H; Cole AL; Hur JY; Li Y; Zheng H
PLoS One; 2013; 8(11):e80706. PubMed ID: 24278307
[TBL] [Abstract][Full Text] [Related]
34. Progress toward valid transgenic mouse models for Alzheimer's disease.
Guénette SY; Tanzi RE
Neurobiol Aging; 1999; 20(2):201-11. PubMed ID: 10537029
[TBL] [Abstract][Full Text] [Related]
35. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
36. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.
Kurt MA; Davies DC; Kidd M; Duff K; Rolph SC; Jennings KH; Howlett DR
Exp Neurol; 2001 Sep; 171(1):59-71. PubMed ID: 11520121
[TBL] [Abstract][Full Text] [Related]
37. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
[TBL] [Abstract][Full Text] [Related]
38. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease.
Aso E; Lomoio S; López-González I; Joda L; Carmona M; Fernández-Yagüe N; Moreno J; Juvés S; Pujol A; Pamplona R; Portero-Otin M; Martín V; Díaz M; Ferrer I
Brain Pathol; 2012 Sep; 22(5):636-53. PubMed ID: 22188425
[TBL] [Abstract][Full Text] [Related]
39. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.
Andorfer C; Kress Y; Espinoza M; de Silva R; Tucker KL; Barde YA; Duff K; Davies P
J Neurochem; 2003 Aug; 86(3):582-90. PubMed ID: 12859672
[TBL] [Abstract][Full Text] [Related]
40. Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.
Woodhouse A; Shepherd CE; Sokolova A; Carroll VL; King AE; Halliday GM; Dickson TC; Vickers JC
Acta Neuropathol; 2009 Jan; 117(1):19-29. PubMed ID: 19015863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
